Austedo is NOT appropriate for this patient
You are describing tardive dyskinesia (TD), and Austedo (deutetrabenazine) is actually FDA-approved to TREAT this condition, not cause it. The significant tongue movements and lip-smacking you're observing are classic orofacial manifestations of TD—an involuntary movement disorder typically caused by long-term dopamine antagonist exposure 1.
Critical Clarification: What is Austedo?
Austedo (deutetrabenazine) is a VMAT2 inhibitor specifically FDA-approved for treating:
- Tardive dyskinesia (movements in face, tongue, or other body parts that cannot be controlled)
- Chorea associated with Huntington's disease
This is fundamentally different from dextromethorphan/quinidine, which you may be confusing it with. Let me address both:
If You're Asking About Austedo (Deutetrabenazine):
YES—Austedo IS appropriate for treating TD with orofacial dyskinesia
Austedo is specifically indicated for exactly what you're describing: involuntary tongue movements and lip-smacking characteristic of tardive dyskinesia 2.
Key Treatment Considerations:
Dosing: Start low and titrate weekly based on response and tolerability. Maximum dose is 48 mg/day (or 36 mg/day if on strong CYP2D6 inhibitors) 2
Monitoring requirements:
Common adverse effects: Somnolence, sedation, parkinsonism, akathisia 2
Contraindications:
- Active liver disease
- Concurrent use with reserpine, MAOIs, tetrabenazine, or valbenazine
- Patients with suicidal ideation (in Huntington's disease context) 2
If You're Asking About Dextromethorphan/Quinidine (Nuedexta):
NO—Dextromethorphan/quinidine is NOT appropriate for TD
Dextromethorphan/quinidine is FDA-approved only for pseudobulbar affect (pathological laughing/crying), NOT for tardive dyskinesia 5, 6, 7.
The 2019 AGS Beers Criteria specifically advises CAUTION with dextromethorphan/quinidine in dementia patients due to limited efficacy for behavioral symptoms while increasing fall risk and drug interactions 8. It should NOT be used for TD.
While one small pilot study explored dextromethorphan/quinidine for levodopa-induced dyskinesia in Parkinson's disease 9, this is:
- A completely different condition than TD
- Based on preliminary evidence only
- Not FDA-approved for this indication
First-Line Management Algorithm for TD:
Confirm the diagnosis: Use AIMS to document baseline severity 3, 4
Identify the causative agent: Review all current and past dopamine antagonists (typical antipsychotics > atypical antipsychotics) 3, 1, 3
Risk-benefit assessment:
Initiate VMAT2 inhibitor (Austedo or valbenazine):
Avoid common pitfalls:
Critical Safety Considerations:
QTc prolongation risk: Both quinidine (in dextromethorphan/quinidine) and Austedo can prolong QTc 1, 8, 2. Obtain baseline ECG if:
- Age >65 years
- Cardiac history
- Concurrent QT-prolonging medications
- Electrolyte abnormalities
Drug interactions: Austedo requires dose reduction (max 36 mg/day) with strong CYP2D6 inhibitors like paroxetine, fluoxetine, quinidine, or bupropion 2
Sedation: Warn patients about driving/operating machinery until stable on medication; avoid alcohol and other CNS depressants 2